Home> Products> slower

{ "products": [ { "_id": "693c0f0df827a9801a26dcd7", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Isosorbide mononitrate IP 60mg Tablets", "description": "CARDULES ISMN SR 60 delivers Isosorbide Mononitrate IP 60mg in a sustained-release tablet form, designed for long-term prevention of angina in patients with coronary artery disease. Produced by Steris Healthcare Pvt Ltd, this formulation ensures steady drug release over 12-24 hours, optimizing cardiovascular protection with once-daily dosing convenience. It supports heart health by enhancing blood flow without the peaks and troughs of immediate-release options.​\n\nProduct Overview\nCARDULES ISMN SR 60 contains Isosorbide Mononitrate IP 60mg per sustained-release tablet, a pure nitrate metabolite that bypasses first-pass liver metabolism for consistent bioavailability. The SR technology employs a polymer matrix to gradually liberate the active ingredient, maintaining therapeutic plasma levels throughout the day and minimizing tolerance development associated with frequent dosing. Available in strips of 10 tablets, it features a film-coated exterior for easy swallowing and gastro-resistant properties to protect against stomach acid degradation.​\n\nThis higher 60mg strength suits patients requiring intensified prophylaxis after initial titration from lower doses like 30mg or 40mg. It integrates seamlessly into comprehensive cardiac regimens alongside beta-blockers, statins, or aspirin, under cardiologist supervision. Quality manufacturing adheres to IP standards, ensuring purity above 99% with low impurity profiles for safety in chronic use.​\n\nKey Uses\nCARDULES ISMN SR 60 primarily prevents chronic stable angina pectoris by dilating coronary arteries and reducing myocardial oxygen demand during exertion. Patients experience fewer episodes of chest tightness, pressure, or discomfort triggered by physical activity, stress, or cold exposure.​\n\nIt manages coronary artery disease (CAD) by improving collateral circulation and easing ischemia in narrowed vessels. Often prescribed post-angioplasty or alongside lifestyle modifications, it stabilizes symptoms for enhanced daily functioning.​\n\nAdditionally, it supports adjunctive therapy in congestive heart failure or post-myocardial infarction recovery, where vasodilation unloads the heart. Not for acute attacks—use sublingual nitroglycerin instead—but vital for long-term risk reduction.​\n\nMajor Benefits\nThe sustained-release profile of CARDULES ISMN SR 60 provides 24-hour angina prevention with single morning dosing, improving adherence over multiple-daily regimens. This steady vasodilation lowers preload via venous pooling and afterload via arterial relaxation, cutting oxygen consumption by up to 20-30% during stress.​\n\nPatients report increased exercise tolerance, with treadmill tests showing delayed onset of ST-segment depression. Enhanced myocardial perfusion boosts energy levels, enabling return to work, hobbies, or family activities without fear of sudden symptoms.​\n\nCompared to shorter-acting nitrates, tolerance buildup is slower due to a nitrate-free interval built into once-daily use. Cost-effective at higher strengths, it reduces overall healthcare visits and hospitalization risks from unstable angina.​\n\nBenefit\tMechanism\tClinical Advantage\nAngina Prevention\tVasodilation reduces preload/afterload ​\tFewer episodes, better quality of life\nExercise Capacity\tImproved coronary flow ​\tExtended activity duration by 50%+\nDosing Simplicity\tSR once daily ​\t90% adherence rate vs. multiple doses\nHeart Protection\tLowers ischemia risk. ​\tReduced MI recurrence\nPotential Side Effects\nCommon effects include headache (orthostatic or throbbing), especially in the first week, resolving with hydration and dose acclimation—acetaminophen helps manage it. Dizziness, lightheadedness, or postural hypotension may occur; rise slowly from sitting.​\n\nGastrointestinal upset like nausea or flushing affects 5-10% initially. Avoid alcohol or PDE5 inhibitors (e.g., sildenafil) to prevent severe hypotension.​\n\nRarely, reflex tachycardia, rash, or methemoglobinemia arises; monitor liver enzymes in prolonged use. Contraindicated in severe anemia, glaucoma, or recent PDE5 intake—discontinue if allergic reactions appear.​\n\nDosage Guidelines\nInitiate at 30-40mg daily, titrating to 60mg once in the morning on an empty stomach for optimal absorption. Swallow whole; do not crush. A 10-12 hour nitrate-free window (nighttime) prevents tolerance.​\n\nAdjust for renal/hepatic impairment; max 120mg/day. Store below 25°C. Regular ECG and BP checks ensure efficacy.​\nConclusion\nCARDULES ISMN SR 60 stands as a cornerstone in angina prophylaxis, empowering CAD patients with reliable, sustained vascular relief from Steris Healthcare. Consistent use alongside diet, exercise, and smoking cessation maximizes outcomes, but cardiologist oversight remains essential for safety", "price": 155.0, "discountamount": 47.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2244, "imageuri": "https://productimages.withfloats.com/actual/693c0f14d878634fd7a965ca.png", "tileimageuri": "https://productimages.withfloats.com/tile/693c0f14d878634fd7a965ca.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-12T12:48:13.762Z", "updatedon": "2025-12-16T05:41:10.59Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/isosorbide-mononitrate-ip-60mg-tablets/2244", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "CARDULES ISMN SR 60", "category": "cardiology", "tags": [ "Isosorbide mononitrate IP 60mg Tablets", "coronary artery disease", "supports heart health by enhancing blood flow", "gastro-resistant properties to protect against stomach acid", "Contraindicated in severe anemia, glaucoma, or recent PDE5" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "66d999cc236afd258ed10348", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Nintedanib 100 mg", "description": "NINTEDONE 100 \nNintedanib 100 mg is a cutting-edge oral medication designed to combat progressive lung conditions and certain cancers, offering hope to patients facing debilitating fibrotic diseases. As a small-molecule tyrosine kinase inhibitor, it targets key pathways involved in abnormal cell growth and tissue scarring, making it a vital therapy for idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated interstitial lung disease (SSc-ILD), and progressive fibrosing interstitial lung diseases (PF-ILD). Manufactured to high standards, this formulation delivers precise dosing in a convenient capsule form, ensuring consistent absorption and efficacy for long-term management.​\n\nUses of Nintedanib 100 mg\nNintedanib 100 mg stands out for its approved indications in slowing the decline of lung function in adults with IPF, a chronic and fatal lung disease characterized by progressive scarring of lung tissue. It is also indicated for SSc-ILD, where it helps manage lung fibrosis associated with systemic sclerosis, and PF-ILD, covering other chronic fibrosing lung conditions with a progressive phenotype. Beyond pulmonary fibrosis, Nintedanib has shown utility in oncology, particularly when combined with docetaxel for second-line treatment of advanced non-small cell lung cancer (NSCLC) of adenocarcinoma tumor histology, inhibiting tumor angiogenesis and growth.​\n\nThis medication addresses the underlying fibrotic processes by restricting fibroblast proliferation and migration, which are central to lung tissue damage. In clinical practice, physicians prescribe Nintedanib 100 mg for patients with confirmed diagnoses via high-resolution CT scans or lung biopsies, often after other treatments fail. Its versatility extends to off-label considerations in other cancers like pancreatic or colorectal, though primary use remains in respiratory fibrosis and lung cancer, providing a targeted approach where traditional therapies fall short.​\n\nKey Benefits of Nintedanib 100 mg\nOne of the primary benefits of Nintedanib 100 mg is its proven ability to reduce the rate of forced vital capacity (FVC) decline, a key measure of lung function, by up to 50% in IPF patients compared to placebo in landmark trials. This translates to slower disease progression, fewer acute exacerbations, and improved quality of life, allowing patients to maintain daily activities longer. The oral administration enhances patient compliance, avoiding the need for infusions or hospital visits.​\n\nSlows Fibrosis Progression: By inhibiting multiple tyrosine kinases, it curbs excessive scar tissue formation in the lungs, preserving respiratory capacity over time.​\n\nAnti-Angiogenic Effects: In cancer settings, it blocks vascular endothelial growth factor receptors (VEGFR), reducing tumor blood supply and metastasis risk.​\n\nBroad-Spectrum Kinase Inhibition: Targets fibroblast growth factor receptors (FGFR), platelet-derived growth factor receptors (PDGFR), and others, addressing multifaceted disease pathways.​\n\nManageable Long-Term Use: Clinical data supports sustained benefits with dose adjustments, minimizing hospitalizations for respiratory failure.​\n\nImproved Survival Metrics: In combination therapies for NSCLC, it extends progression-free survival, offering valuable time for patients.​\n\nThese advantages make Nintedanib 100 mg a cornerstone in modern pulmonology and oncology, backed by phase III trials demonstrating statistically significant outcomes in diverse patient populations.​\n\nSide Effects of Nintedanib 100 mg\nWhile effective, Nintedanib 100 mg can cause gastrointestinal side effects as the most common issue, affecting over 60% of users primarily due to its impact on kinase signaling in the gut. Diarrhea often starts within the first two weeks and is typically manageable with dose reduction or antidiarrheal agents like loperamide. Other frequent effects include nausea, vomiting, and decreased appetite, which may lead to weight loss if not addressed.​\n\nMore serious side effects warrant close monitoring:\n\nLiver Enzyme Elevations: Hepatotoxicity occurs in about 10-15% of patients, necessitating monthly liver function tests, especially in those with pre-existing liver conditions.​\n\nCardiovascular Risks: Potential for arterial thromboembolism or hypertension; baseline cardiac evaluation is recommended.​\n\nBleeding Events: Due to VEGF inhibition, minor bleeding like epistaxis is common, but gastrointestinal hemorrhage requires immediate attention.​\n\nRare but Severe: Interstitial lung disease progression (paradoxical worsening), perforations, or severe infections in immunocompromised patients.​\n\nPatients should report persistent diarrhea, abdominal pain, jaundice, or unusual fatigue promptly. Contraindications include pregnancy (category D), active bleeding, or hypersensitivity, with strong recommendations against use in moderate to severe hepatic impairment.​\n\nDosage and Administration Insights\nTypically initiated at 150 mg twice daily for IPF and ILD, Nintedanib 100 mg allows for flexible dosing—starting lower at 100 mg BID if tolerated poorly, with food to reduce GI upset. For NSCLC, it's 200 mg BID with docetaxel cycles. Regular monitoring every 2-3 months adjusts for tolerance, emphasizing adherence to slow disease modification.​\n\nConclusion\nNintedanib 100 mg represents a breakthrough in managing progressive fibrotic lung diseases and select cancers, delivering targeted inhibition of fibrotic and angiogenic pathways for tangible clinical benefits. Its ability to slow FVC decline, enhance patient quality of life, and integrate into combination regimens underscores its value, despite manageable side effects like diarrhea that respond well to supportive care. For those battling IPF, SSc-ILD, or NSCLC, Nintedanib 100 mg offers a proactive defense against relentless progression, empowering longer, more active lives under specialist guidance.​", "price": 795.0, "discountamount": 296.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "one capsule", "weight loss", "scar tissue", "key players", "Key Benefits", "lung function", "initial stages", "abdominal pain", "fibrous tissue", "key ingredient", "Bleeding Events", "fibrotic tissue", "daily activities", "tyrosine kinases", "fibrotic process", "Nintedanib 100 mg", "multiple pathways", "active ingredient", "sudden worsenings", "crucial medication", "recommended dosage", "Decreased Appetite", "signaling pathways", "multiple receptors", "overall well-being", "disease progression", "acute exacerbations", "healthcare provider", "Common side effects", "elevated liver enzymes", "Gastrointestinal Issues", "other fibrotic diseases", "Liver Enzyme Elevations", "tyrosine kinase inhibitor", "progressive lung conditions", "other fibrotic lung diseases", "idiopathic pulmonary fibrosis", "potent pharmaceutical formulation", "fibroblast growth factor receptor", "platelet-derived growth factor receptor", "vascular endothelial growth factor receptor" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1971, "imageuri": "https://productimages.withfloats.com/actual/66d999d4f2036c2969cdeca8.png", "tileimageuri": "https://productimages.withfloats.com/tile/66d999d4f2036c2969cdeca8.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-09-05T11:45:16.665Z", "updatedon": "2025-12-11T07:34:33.738Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/nintedanib-100-mg/1971", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "NINTEDONE 100 ", "category": "NEPHROLOGYRANGE", "tags": [ "lung conditions and certain cancers", "Nintedanib 100 mg", "pulmonary fibrosis (IPF)", "fibrosis and lung cancer" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "66619278db9fdd21801ef284", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "SEIZMET TRIO 0.3 ", "description": "SEIZMET TRIO 0.3 \nGlimepiride (2mg), Metformin SR (500mg), Voglibose (0.3mg)\nIntroduction to SEIZMET TRIO 0.3\nSEIZMET TRIO 0.3 is a combination medication that includes Glimepiride 2mg, Metformin Hydrochloride Sustained Release (SR) 500mg, and Voglibose 0.3mg. This medication is primarily used for the management of type 2 diabetes mellitus. By combining the complementary mechanisms of Glimepiride, Metformin, and Voglibose, SEIZMET TRIO 0.3 offers comprehensive glycemic control, helping patients manage their blood sugar levels effectively.\n\nWhat are Glimepiride, Metformin, and Voglibose?\nOverview of Glimepiride\nGlimepiride is a sulfonylurea that helps control blood sugar levels by stimulating the pancreas to release more insulin. It works by closing ATP-sensitive potassium channels in the pancreatic beta cells, leading to insulin secretion.\n\nOverview of Metformin\nMetformin is a biguanide that helps lower blood sugar levels by improving the body's sensitivity to insulin and reducing the amount of glucose produced by the liver. It also enhances peripheral glucose uptake and utilization. The sustained-release formulation ensures a prolonged effect throughout the day.\n\nOverview of Voglibose\nVoglibose is an alpha-glucosidase inhibitor that helps control blood sugar levels by slowing the digestion and absorption of carbohydrates in the small intestine. This leads to a slower and lower rise in blood glucose levels after meals.\n\nBenefits of SEIZMET TRIO 0.3\nEffective Blood Sugar Management\nTriple Mechanism of Action: Glimepiride stimulates insulin secretion, Metformin improves insulin sensitivity and reduces hepatic glucose production, and Voglibose slows carbohydrate absorption. This comprehensive approach offers robust glycemic control.\nPostprandial and Fasting Glucose Control: This combination helps manage both postprandial (after-meal) and fasting blood sugar levels, offering all-around glycemic control.\nSupport for Diabetes Management\nDiet and Exercise Adjunct: SEIZMET TRIO 0.3 is an excellent adjunct to diet and exercise, helping patients achieve better blood sugar control when lifestyle modifications alone are insufficient.\nReduced Risk of Complications: By maintaining more stable blood sugar levels, SEIZMET TRIO 0.3 can help reduce the risk of long-term complications associated with diabetes, such as cardiovascular disease, neuropathy, and retinopathy.\nAdditional Health Benefits\nWeight Management: Metformin is often associated with weight neutrality or modest weight loss, making it a favorable option for overweight or obese patients.\nImproved Glycemic Control: Voglibose’s action on slowing carbohydrate absorption leads to better control over postprandial spikes, contributing to overall glycemic stability.\nHow to Use SEIZMET TRIO 0.3\nDosage and Administration\nRecommended Dosage: The typical dosage of SEIZMET TRIO 0.3 is one tablet taken once or twice daily, depending on your healthcare provider's instructions. The dosage may be adjusted based on individual response and blood sugar levels.\nAdministration: Take the tablet with meals to reduce the risk of gastrointestinal discomfort and enhance the effectiveness of Metformin and Voglibose. Swallow the tablet whole with a full glass of water.\nGuidelines for Optimal Use\nConsistent Use: For best results, take SEIZMET TRIO 0.3 regularly as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regularly check your blood sugar levels to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/seizmet-trio-0-3-133446", "price": 166.9, "discountamount": 50.07, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "3", "day", "body", "Diet", "EMAIL", "Order", "liver", "water", "meals", "amount", "slower", "option", "Action", "Support", "Overview", "pancreas", "readings", "digestion", "biguanide", "Voglibose", "one tablet", "lower rise", "overweight", "Guidelines", "full glass", "neuropathy", "utilization", "Adjustments", "information", "retinopathy", "Optimal Use", "Introduction", "Metformin SR", "SEIZMET TRIO", "best results", "sterisonline", "Reduced Risk", "instructions", "sterispharma", "sulfonylurea", "effectiveness", "CALL/WHATSAPP", "carbohydrates", "Administration", "obese patients", "typical dosage", "treatment plan", "Consistent Use", "Glimepiride 2mg", "small intestine", "Exercise Adjunct", "prolonged effect", "Triple Mechanism", "excellent adjunct", "Weight Management", "weight neutrality", "insulin secretion", "Recommended Dosage", "modest weight loss", "blood sugar control", "Diabetes Management", "individual response", "postprandial spikes", "healthcare provider", "insulin sensitivity", "blood glucose levels", "pancreatic beta cells", "cardiovascular disease", "combination medication", "comprehensive approach", "Fasting Glucose Control", "long-term complications", "robust glycemic control", "lifestyle modifications", "carbohydrate absorption", "type 2 diabetes mellitus", "complementary mechanisms", "peripheral glucose uptake", "stable blood sugar levels", "hepatic glucose production", "Additional Health Benefits", "overall glycemic stability", "alpha-glucosidase inhibitor", "gastrointestinal discomfort", "sustained-release formulation", "comprehensive glycemic control", "ATP-sensitive potassium channels", "Effective Blood Sugar Management", "Metformin Hydrochloride Sustained Release" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1453, "imageuri": "https://productimages.withfloats.com/actual/6661927b487c46164ce4b1f6.png", "tileimageuri": "https://productimages.withfloats.com/tile/6661927b487c46164ce4b1f6.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T10:42:00.595Z", "updatedon": "2024-06-29T07:23:34.909Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/seizmet-trio-0-3-/1453", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "SEIZMET TRIO 0.3 ", "category": "DIABETIC RANGE", "tags": [ "SEIZMET TRIO 0.3", "Glimepiride (2mg)", "Metformin SR (500mg)", "Voglibose (0.3mg)", "Glimepiride 2mg side effects", "glimepiride + metformin", "Glimepiride 2mg price", "Glimepiride 2mg Uses in Hindi" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "666191664515df1748621e0b", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "SEIZMET TRIO 0.2 ", "description": "SEIZMET TRIO 0.2 \nGlimepiride (2mg), Metformin SR (500mg), Voglibose (0.2mg)\nIntroduction to SEIZMET TRIO 0.2\nSEIZMET TRIO 0.2 is a combination medication that includes Glimepiride 2mg, Metformin Hydrochloride Sustained Release (SR) 500mg, and Voglibose 0.2mg. This medication is primarily used for the management of type 2 diabetes mellitus. By combining the complementary mechanisms of Glimepiride, Metformin, and Voglibose, SEIZMET TRIO 0.2 offers comprehensive glycemic control, helping patients manage their blood sugar levels effectively.\n\nWhat are Glimepiride, Metformin, and Voglibose?\nOverview of Glimepiride\nGlimepiride is a sulfonylurea that helps control blood sugar levels by stimulating the pancreas to release more insulin. It works by closing ATP-sensitive potassium channels in the pancreatic beta cells, leading to insulin secretion.\n\nOverview of Metformin\nMetformin is a biguanide that helps lower blood sugar levels by improving the body's sensitivity to insulin and reducing the amount of glucose produced by the liver. It also enhances peripheral glucose uptake and utilization. The sustained-release formulation ensures a prolonged effect throughout the day.\n\nOverview of Voglibose\nVoglibose is an alpha-glucosidase inhibitor that helps control blood sugar levels by slowing the digestion and absorption of carbohydrates in the small intestine. This leads to a slower and lower rise in blood glucose levels after meals.\n\nBenefits of SEIZMET TRIO 0.2\nEffective Blood Sugar Management\nTriple Mechanism of Action: Glimepiride stimulates insulin secretion, Metformin improves insulin sensitivity and reduces hepatic glucose production, and Voglibose slows carbohydrate absorption. This comprehensive approach offers robust glycemic control.\nPostprandial and Fasting Glucose Control: This combination helps manage both postprandial (after-meal) and fasting blood sugar levels, offering all-around glycemic control.\nSupport for Diabetes Management\nDiet and Exercise Adjunct: SEIZMET TRIO 0.2 is an excellent adjunct to diet and exercise, helping patients achieve better blood sugar control when lifestyle modifications alone are insufficient.\nReduced Risk of Complications: By maintaining more stable blood sugar levels, SEIZMET TRIO 0.2 can help reduce the risk of long-term complications associated with diabetes, such as cardiovascular disease, neuropathy, and retinopathy.\nAdditional Health Benefits\nWeight Management: Metformin is often associated with weight neutrality or modest weight loss, making it a favorable option for overweight or obese patients.\nImproved Glycemic Control: Voglibose’s action on slowing carbohydrate absorption leads to better control over postprandial spikes, contributing to overall glycemic stability.\nHow to Use SEIZMET TRIO 0.2\nDosage and Administration\nRecommended Dosage: The typical dosage of SEIZMET TRIO 0.2 is one tablet taken once or twice daily, depending on your healthcare provider's instructions. The dosage may be adjusted based on individual response and blood sugar levels.\nAdministration: Take the tablet with meals to reduce the risk of gastrointestinal discomfort and enhance the effectiveness of Metformin and Voglibose. Swallow the tablet whole with a full glass of water.\nGuidelines for Optimal Use\nConsistent Use: For best results, take SEIZMET TRIO 0.2 regularly as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regularly check your blood sugar levels to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/seizmet-trio-0-2-133445", "price": 155.9, "discountamount": 46.77, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "day", "Diet", "body", "liver", "meals", "water", "Order", "EMAIL", "option", "amount", "slower", "Action", "Support", "readings", "Overview", "pancreas", "Improved", "Voglibose", "digestion", "biguanide", "neuropathy", "full glass", "lower rise", "overweight", "one tablet", "Guidelines", "information", "Adjustments", "retinopathy", "utilization", "Optimal Use", "Metformin SR", "best results", "Introduction", "SEIZMET TRIO", "sterisonline", "Reduced Risk", "instructions", "sterispharma", "sulfonylurea", "effectiveness", "CALL/WHATSAPP", "carbohydrates", "Administration", "obese patients", "typical dosage", "treatment plan", "Consistent Use", "Glimepiride 2mg", "small intestine", "Exercise Adjunct", "prolonged effect", "Triple Mechanism", "excellent adjunct", "Weight Management", "weight neutrality", "insulin secretion", "Recommended Dosage", "modest weight loss", "blood sugar control", "Diabetes Management", "individual response", "postprandial spikes", "healthcare provider", "insulin sensitivity", "blood glucose levels", "pancreatic beta cells", "cardiovascular disease", "combination medication", "comprehensive approach", "Fasting Glucose Control", "long-term complications", "robust glycemic control", "lifestyle modifications", "carbohydrate absorption", "type 2 diabetes mellitus", "complementary mechanisms", "peripheral glucose uptake", "stable blood sugar levels", "hepatic glucose production", "Additional Health Benefits", "overall glycemic stability", "alpha-glucosidase inhibitor", "gastrointestinal discomfort", "sustained-release formulation", "comprehensive glycemic control", "ATP-sensitive potassium channels", "Effective Blood Sugar Management", "Metformin Hydrochloride Sustained Release" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1452, "imageuri": "https://productimages.withfloats.com/actual/6661916a8e77bb2c7156e563.png", "tileimageuri": "https://productimages.withfloats.com/tile/6661916a8e77bb2c7156e563.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T10:37:26.597Z", "updatedon": "2024-06-29T07:23:47.697Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/seizmet-trio-0-2-/1452", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "SEIZMET TRIO 0.2 ", "category": "DIABETIC RANGE", "tags": [ "SEIZMET TRIO 0.2", "Glimepiride (2mg)", "Metformin SR (500mg)", "Voglibose (0.2mg)", "Glimepiride 2mg side effects", "glimepiride + metformin", "Glimepiride 2mg price", "Glimepiride 2mg Uses in Hindi" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "66616410ccd5ce1a107590a0", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "RAPIGLINIDE VOG 1.0 ", "description": "RAPIGLINIDE VOG 1.0 \nRepaglinide (1mg), Voglibose (0.3mg)\nIntroduction to RAPIGLINIDE VOG 1.0\nRAPIGLINIDE VOG 1.0 is a combination medication that includes Repaglinide 1mg and Voglibose 0.3mg. This medication is primarily used for the management of type 2 diabetes mellitus. By combining the complementary mechanisms of Repaglinide and Voglibose, RAPIGLINIDE VOG 1.0 offers comprehensive glycemic control, helping patients manage their blood sugar levels effectively.\n\nWhat are Repaglinide and Voglibose?\nOverview of Repaglinide\nRepaglinide is a meglitinide analog that helps control blood sugar levels by stimulating the pancreas to produce more insulin. It works by closing ATP-dependent potassium channels in the pancreatic beta-cell membrane, which leads to the opening of calcium channels and insulin release.\n\nOverview of Voglibose\nVoglibose is an alpha-glucosidase inhibitor that helps control blood sugar levels by slowing the digestion and absorption of carbohydrates in the small intestine. This leads to a slower and lower rise in blood glucose levels after meals.\n\nBenefits of RAPIGLINIDE VOG 1.0\nEffective Blood Sugar Management\nPostprandial Glucose Control: Repaglinide helps reduce blood sugar spikes after meals by stimulating rapid and short-acting insulin secretion. Voglibose complements this by slowing the absorption of carbohydrates, leading to a more gradual increase in blood glucose levels.\nComprehensive Glycemic Control: The combination of these two medications provides a dual mechanism of action that targets both insulin secretion and carbohydrate absorption, offering comprehensive blood sugar management.\nSupport for Diabetes Management\nDiet and Exercise Adjunct: RAPIGLINIDE VOG 1.0 is an excellent adjunct to diet and exercise, helping patients achieve better blood sugar control when lifestyle modifications alone are insufficient.\nReduced Risk of Complications: By maintaining more stable blood sugar levels, RAPIGLINIDE VOG 1.0 can help reduce the risk of long-term complications associated with diabetes, such as cardiovascular disease, neuropathy, and retinopathy.\nHow to Use RAPIGLINIDE VOG 1.0\nDosage and Administration\nRecommended Dosage: The typical dosage of RAPIGLINIDE VOG 1.0 is one tablet taken before each main meal. Your healthcare provider may adjust the dosage based on your individual response and blood sugar levels.\nAdministration: Take the tablet before each meal to enhance its effectiveness in controlling postprandial blood sugar spikes. Swallow the tablet whole with a full glass of water.\nGuidelines for Optimal Use\nConsistent Use: For best results, take RAPIGLINIDE VOG 1.0 regularly as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regularly check your blood sugar levels to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/rapiglinide-vog-1-0-134237", "price": 189.0, "discountamount": 56.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "Diet", "rapid", "Order", "EMAIL", "meals", "water", "slower", "action", "Support", "opening", "patients", "pancreas", "readings", "Benefits", "Overview", "Voglibose", "digestion", "main meal", "one tablet", "neuropathy", "full glass", "lower rise", "Guidelines", "information", "Adjustments", "Optimal Use", "Repaglinide", "retinopathy", "sterisonline", "sterispharma", "best results", "Introduction", "Reduced Risk", "CALL/WHATSAPP", "carbohydrates", "effectiveness", "typical dosage", "Consistent Use", "dual mechanism", "treatment plan", "Administration", "insulin release", "RAPIGLINIDE VOG", "small intestine", "two medications", "gradual increase", "calcium channels", "Exercise Adjunct", "excellent adjunct", "Recommended Dosage", "meglitinide analog", "Diabetes Management", "individual response", "healthcare provider", "blood sugar control", "blood glucose levels", "combination medication", "cardiovascular disease", "long-term complications", "lifestyle modifications", "carbohydrate absorption", "complementary mechanisms", "type 2 diabetes mellitus", "stable blood sugar levels", "alpha-glucosidase inhibitor", "Postprandial Glucose Control", "pancreatic beta-cell membrane", "short-acting insulin secretion", "comprehensive glycemic control", "postprandial blood sugar spikes", "ATP-dependent potassium channels", "Effective Blood Sugar Management", "comprehensive blood sugar management" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1415, "imageuri": "https://productimages.withfloats.com/actual/666164117b1fc3f9dd4c947c.png", "tileimageuri": "https://productimages.withfloats.com/tile/666164117b1fc3f9dd4c947c.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T07:24:00.417Z", "updatedon": "2024-06-29T10:15:40.38Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/rapiglinide-vog-1-0-/1415", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "RAPIGLINIDE VOG 1.0 ", "category": "DIABETIC RANGE", "tags": [ "RAPIGLINIDE VOG 1.0", "Repaglinide (1mg)", "Voglibose (0.3mg)", "Repaglinide 1 mg uses", "Repaglinide 1 mg price", "Repaglinide mechanism of action", "" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "66616318d91d281c30c74f57", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "RAPIGLINIDE VOG 0.5 ", "description": "RAPIGLINIDE VOG 0.5 \nRepaglinide (0.5mg), Voglibose (0.3mg)\nIntroduction to RAPIGLINIDE VOG 0.5\nRAPIGLINIDE VOG 0.5 is a combination medication that includes Repaglinide 0.5mg and Voglibose 0.3mg. This medication is primarily used for the management of type 2 diabetes mellitus. By combining the complementary mechanisms of Repaglinide and Voglibose, RAPIGLINIDE VOG 0.5 offers comprehensive glycemic control, helping patients manage their blood sugar levels effectively.\n\nWhat are Repaglinide and Voglibose?\nOverview of Repaglinide\nRepaglinide is a meglitinide analog that helps control blood sugar levels by stimulating the pancreas to produce more insulin. It works by closing ATP-dependent potassium channels in the pancreatic beta-cell membrane, which leads to the opening of calcium channels and insulin release.\n\nOverview of Voglibose\nVoglibose is an alpha-glucosidase inhibitor that helps control blood sugar levels by slowing the digestion and absorption of carbohydrates in the small intestine. This leads to a slower and lower rise in blood glucose levels after meals.\n\nBenefits of RAPIGLINIDE VOG 0.5\nEffective Blood Sugar Management\nPostprandial Glucose Control: Repaglinide helps reduce blood sugar spikes after meals by stimulating rapid and short-acting insulin secretion. Voglibose complements this by slowing the absorption of carbohydrates, leading to a more gradual increase in blood glucose levels.\nComprehensive Glycemic Control: The combination of these two medications provides a dual mechanism of action that targets both insulin secretion and carbohydrate absorption, offering comprehensive blood sugar management.\nSupport for Diabetes Management\nDiet and Exercise Adjunct: RAPIGLINIDE VOG 0.5 is an excellent adjunct to diet and exercise, helping patients achieve better blood sugar control when lifestyle modifications alone are insufficient.\nReduced Risk of Complications: By maintaining more stable blood sugar levels, RAPIGLINIDE VOG 0.5 can help reduce the risk of long-term complications associated with diabetes, such as cardiovascular disease, neuropathy, and retinopathy.\nHow to Use RAPIGLINIDE VOG 0.5\nDosage and Administration\nRecommended Dosage: The typical dosage of RAPIGLINIDE VOG 0.5 is one tablet taken before each main meal. Your healthcare provider may adjust the dosage based on your individual response and blood sugar levels.\nAdministration: Take the tablet before each meal to enhance its effectiveness in controlling postprandial blood sugar spikes. Swallow the tablet whole with a full glass of water.\nGuidelines for Optimal Use\nConsistent Use: For best results, take RAPIGLINIDE VOG 0.5 regularly as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regularly check your blood sugar levels to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/rapiglinide-vog-0-5-134238", "price": 145.0, "discountamount": 43.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "Diet", "rapid", "Order", "EMAIL", "meals", "water", "slower", "action", "Support", "opening", "patients", "pancreas", "readings", "Benefits", "Overview", "Voglibose", "digestion", "main meal", "one tablet", "neuropathy", "full glass", "lower rise", "Guidelines", "information", "Adjustments", "Optimal Use", "Repaglinide", "retinopathy", "sterisonline", "sterispharma", "best results", "Introduction", "Reduced Risk", "CALL/WHATSAPP", "carbohydrates", "effectiveness", "typical dosage", "Consistent Use", "dual mechanism", "treatment plan", "Administration", "insulin release", "RAPIGLINIDE VOG", "small intestine", "two medications", "gradual increase", "calcium channels", "Exercise Adjunct", "excellent adjunct", "Recommended Dosage", "meglitinide analog", "Diabetes Management", "individual response", "healthcare provider", "blood sugar control", "blood glucose levels", "combination medication", "cardiovascular disease", "long-term complications", "lifestyle modifications", "carbohydrate absorption", "complementary mechanisms", "type 2 diabetes mellitus", "stable blood sugar levels", "alpha-glucosidase inhibitor", "Postprandial Glucose Control", "pancreatic beta-cell membrane", "short-acting insulin secretion", "comprehensive glycemic control", "postprandial blood sugar spikes", "ATP-dependent potassium channels", "Effective Blood Sugar Management", "comprehensive blood sugar management" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1413, "imageuri": "https://productimages.withfloats.com/actual/6661631cc40ee9be019a5fd2.png", "tileimageuri": "https://productimages.withfloats.com/tile/6661631cc40ee9be019a5fd2.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T07:19:52.782Z", "updatedon": "2024-06-29T10:18:42.752Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/rapiglinide-vog-0-5-/1413", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "RAPIGLINIDE VOG 0.5 ", "category": "DIABETIC RANGE", "tags": [ "RAPIGLINIDE VOG 0.5", "Repaglinide (0.5mg),", "Voglibose (0.3mg)", "voglibose 0.3mg price in india", "voglibose 0.3mg uses", "voglibose 0.3mg dosage" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "6943af86161ad9de85f42b10", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Imatinib IP 400mg", "description": "IMATIFLOW 400, containing Imatinib IP 400mg, represents a breakthrough in targeted cancer therapy, offering patients a precise weapon against specific malignancies. This oral medication belongs to the class of tyrosine kinase inhibitors, revolutionizing treatment for conditions once deemed challenging to manage. By blocking abnormal proteins that fuel cancer cell growth, IMATIFLOW 400 helps restore normal cellular function and improves quality of life for many users.​\n\nProduct Overview\nIMATIFLOW 400 is a branded formulation of Imatinib mesylate 400mg, produced to high pharmaceutical standards for consistent efficacy and bioavailability. Each tablet delivers the active ingredient in a film-coated form, designed for once-daily administration with food to enhance absorption and minimize gastrointestinal upset. Developed for adult patients, it targets cancers driven by dysregulated tyrosine kinases like BCR-ABL, c-KIT, and PDGFR, making it a cornerstone in modern oncology protocols.​\n\nThe medication's mechanism hinges on competitive inhibition at the ATP-binding site of these kinases, halting downstream signaling pathways that promote uncontrolled proliferation, survival, and metastasis of malignant cells. Unlike traditional chemotherapy, which broadly attacks dividing cells, IMATIFLOW 400 spares most healthy tissues, leading to a more favorable safety profile. Clinical data from pivotal trials underscore its role as first-line therapy, with high response rates observed within months of initiation.​\n\nPrimary Uses\nIMATIFLOW 400 excels in treating chronic myeloid leukemia (CML), particularly in the chronic phase where it induces deep molecular responses in over 80% of patients. It suppresses the Philadelphia chromosome-positive cells hallmark of CML by inhibiting the BCR-ABL fusion protein, dramatically extending progression-free survival. For newly diagnosed patients, standard dosing starts at 400mg daily, often achieving complete cytogenetic remission.​\n\nIn gastrointestinal stromal tumors (GIST), IMATIFLOW 400 targets KIT or PDGFRA mutations, shrinking unresectable tumors and delaying progression in advanced cases. The recommended dose remains 400mg once daily, with potential escalation to 600-800mg for resistant strains, as per oncology guidelines. It also finds application in dermatofibrosarcoma protuberans (DFSP), aggressive systemic mastocytosis, and certain myelodysplastic syndromes, broadening its utility in precision medicine.​\n\nHealthcare providers monitor response via PCR for BCR-ABL transcripts in CML or imaging for GIST, adjusting therapy based on milestones like major molecular response. Patients with Ph+ acute lymphoblastic leukemia (ALL) may receive it adjunctively, enhancing outcomes when combined with chemotherapy. Overall, IMATIFLOW 400 transforms these diseases from fatal to chronically manageable.​\n\nKey Benefits\nOne standout benefit of IMATIFLOW 400 is its oral convenience, eliminating the need for frequent hospital visits associated with infusions. Response rates exceed 90% in early CML, with many patients achieving treatment-free remission after sustained deep responses, a paradigm shift from interferon-era therapies.​\n\nTumor control in GIST prevents life-threatening complications like bowel obstruction, improving survival from months to years. Its specificity reduces severe toxicities, allowing patients to maintain daily activities, work, and social engagements with minimal disruption. Long-term studies report 10-year survival rates above 80% in CML, underscoring durable efficacy.​\n\nAdditional advantages include cost-effectiveness over biologics and compatibility with supportive care like hydroxyurea for cytoreduction. Fluid retention, while common, responds well to diuretics, preserving cardiac function. For Indian patients, accessible pricing via brands like IMATIFLOW 400 supports equitable care in resource-limited settings.​\n\nPotential Side Effects\nWhile generally well-tolerated, IMATIFLOW 400 can cause edema (swelling in legs or face) in up to 70% of users, managed by dose reduction or supportive measures. Gastrointestinal issues like nausea, vomiting, and diarrhea affect 40-50%, often resolving with antiemetics and dietary adjustments.​\n\nMusculoskeletal pain, cramps, and fatigue occur frequently, alongside rash and abdominal discomfort. Hematologic effects include neutropenia or thrombocytopenia, necessitating regular blood counts. Rare but serious risks involve liver enzyme elevation, heart failure, or hemorrhage; prompt reporting of symptoms like shortness of breath or yellowing skin is crucial.​\n\nAvoid grapefruit juice, as it elevates drug levels, and inform doctors of concurrent medications like CYP3A4 inhibitors. Pregnancy category D status advises contraception, with monitoring for growth retardation in exposed fetuses. Dizziness may impair driving, so caution is essential during initial weeks.​\n\nDosage and Administration Guidelines\nSwallow IMATIFLOW 400 whole with a meal and full glass of water to optimize pharmacokinetics and reduce esophageal irritation. The standard adult dose for CML chronic phase is 400mg daily; for accelerated phase or blast crisis, 600mg. GIST dosing mirrors 400mg, titrated based on tolerance and response.​\n\nRenal or hepatic impairment requires dose adjustments—reduce to 300-400mg in moderate cases. Do not crush or chew tablets. Missed doses should be taken promptly unless near the next, avoiding doubles. Long-term use demands quarterly monitoring of CBC, liver function, and ECG.​\n\nPrecautions and Interactions\nPatients with a cardiac history need baseline echocardiograms, as QT prolongation or effusion risks exist. Drug interactions abound: St. John's wort induces metabolism, reducing efficacy; ketoconazole boosts levels. Vaccines, especially live ones, are contraindicated during therapy.​\n\nRegular dermatologic checks mitigate skin cancer risk from prolonged use. Hydration combats fluid retention, and low-salt diets aid management. Steris Healthcare emphasizes patient education via counseling on adherence for optimal outcomes.​\n\nConclusion\nIMATIFLOW 400 (Imatinib IP 400mg) stands as a testament to targeted therapy's power, offering robust control over CML, GIST, and related cancers with a balance of efficacy and manageability. Its benefits in prolonging life and enhancing daily functioning far outweigh transient side effects for most when monitored diligently. Consult oncologists for personalized plans, ensuring this innovative treatment maximizes hope and health in the fight against cancer.", "price": 1827.0, "discountamount": 540.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2249, "imageuri": "https://productimages.withfloats.com/actual/6943b026ca1b0dcfc6c37820.png", "tileimageuri": "https://productimages.withfloats.com/tile/6943b026ca1b0dcfc6c37820.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-18T07:38:46.766Z", "updatedon": "2025-12-18T07:41:25.851Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/imatinib-ip-400mg/2249", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "IMATIFLOW 400", "category": "NEPHROLOGYRANGE", "tags": [ "Imatinib IP 400mg", "offering robust control over CML.", "related cancers with a balance of efficacy and manageability.", "innovative treatment maximizes hope and health in the fight against cancer.", "cancer therapy.", "fuel cancer cell growth.", "chemotherapy." ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "694004d8504825bb23fa3c1f", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Terbinafine and Itraconazole Tablets 250/100 mg", "description": "CONARIS T100 is a potent antifungal medication formulated with Terbinafine 250 mg and Itraconazole 100 mg. This combination tablet is designed to treat a wide range of fungal infections affecting the skin, nails, and other body parts. Terbinafine and Itraconazole work synergistically to eliminate fungi effectively by targeting their cell membranes and inhibiting growth, providing faster relief from symptoms such as itching, redness, scaling, and discomfort.\n\nFungal infections are common in humid climates and among individuals with compromised immunity, and medications like CONARIS T100 are essential for managing stubborn and recurrent infections. This combination therapy is often prescribed by dermatologists and healthcare professionals for moderate to severe fungal conditions.\n\nUses\n\nCONARIS T100 is used in the treatment of several fungal infections, including:\n\nDermatophytosis (Ringworm): Effective against infections of the skin, hair, and nails caused by dermatophytes.\n\nOnychomycosis (Nail Fungus): Helps in treating fungal infections of fingernails and toenails.\n\nTinea Infections: Treats tinea corporis, tinea cruris, and tinea pedis (athlete’s foot).\n\nCandidiasis: Useful in managing Candida infections affecting the skin and mucous membranes.\n\nRecurrent or Resistant Fungal Infections: Provides stronger antifungal action in cases not responsive to monotherapy.\n\nBenefits\n1. Broad-Spectrum Antifungal Action\n\nThe combination of Terbinafine and Itraconazole ensures effective activity against a wide variety of fungal species, including dermatophytes and yeasts.\n\n2. Faster Symptom Relief\n\nBy targeting fungi at multiple levels, CONARIS T100 helps relieve itching, redness, scaling, and discomfort more quickly than single-agent therapy.\n\n3. Treats Nail and Skin Infections\n\nTerbinafine penetrates nails effectively, while Itraconazole enhances the antifungal spectrum, making the combination ideal for nail and skin fungal infections.\n\n4. Reduces Recurrence\n\nCombination therapy decreases the risk of fungal infections returning by ensuring complete eradication of the pathogen.\n\n5. Convenient Dosage Form\n\nAvailable as an oral tablet, making it easy to administer and suitable for long-term treatment if prescribed.\n\nDosage\n\nAdults: Usually, one tablet of CONARIS T100 daily, preferably after meals, or as directed by a healthcare professional.\n\nTreatment Duration: Varies depending on the type and severity of infection; may range from 2 to 12 weeks for skin infections and longer for nail infections.\n\nImportant: Do not self-adjust dosage or stop treatment prematurely, as incomplete therapy can lead to recurrence or resistance.\n\nSide Effects\n\nCONARIS T100 is generally well tolerated when used as prescribed. Mild side effects may include:\n\nNausea or vomiting\n\nStomach upset or diarrhea\n\nHeadache\n\nDizziness\n\nSerious Side Effects (Rare)\n\nLiver enzyme elevation (monitoring recommended for long-term use)\n\nAllergic reactions such as rash, itching, or swelling\n\nSevere gastrointestinal discomfort\n\nConsult a healthcare provider immediately if you experience jaundice, persistent fatigue, or severe allergic reactions.\n\nPrecautions and Warning\n\nPregnancy and Breastfeeding: Use only if prescribed by a doctor; safety during pregnancy is not fully established.\n\nLiver or Kidney Disorders: Dose adjustment or close monitoring may be required.\n\nDrug Interactions: Inform your doctor about all medications, especially antifungals, statins, or anticoagulants.\n\nAvoid Self-Medication: Fungal infections may mimic other skin conditions, so proper diagnosis is essential.\n\nAlcohol Consumption: Avoid alcohol as it may increase liver toxicity risk.\n\nStorage: Store in a cool, dry place away from direct sunlight and out of children’s reach.\n\nConclusion\n\nCONARIS T100, containing Terbinafine 250 mg and Itraconazole 100 mg, is a reliable and effective treatment for a wide spectrum of fungal infections, including skin, nail, and mucosal infections. Its dual-action antifungal mechanism provides faster symptom relief, reduces recurrence, and improves overall patient outcomes.\n\nWhen used under medical supervision and following prescribed dosage, CONARIS T100 offers a safe and convenient option for managing both common and stubborn fungal infections, ensuring better skin and nail health and enhanced quality of life.", "price": 184.0, "discountamount": 55.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2248, "imageuri": "https://productimages.withfloats.com/actual/694004da351fe1d6b98476e6.png", "tileimageuri": "https://productimages.withfloats.com/tile/694004da351fe1d6b98476e6.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-15T12:53:44.573Z", "updatedon": "2025-12-16T05:44:32.639Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/terbinafine-and-itraconazole-tablets-250-100-mg/2248", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "CONARIS T100", "category": "DERMATALOGY", "tags": [ "terbinafine and itraconazole tablets", "terbinafine and itraconazole together", "terbinafine and itraconazole tablets uses", "terbinafine and itraconazole for nail fungus" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "69400387893a9153e4bd58a8", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Terbinafine and Itraconazole Tablets 250/200mg", "description": "CONARIS T200 is a potent antifungal combination tablet containing Terbinafine 250 mg and Itraconazole 200 mg, formulated to provide effective treatment for various fungal infections. Fungal infections of the skin, nails, and hair are common in India due to the hot and humid climate. These infections can cause itching, redness, scaling, and discomfort, affecting daily life and confidence.\n\nBy combining two powerful antifungal agents, CONARIS T200 targets fungal infections effectively, providing faster relief and improved recovery compared to monotherapy. Terbinafine works by inhibiting fungal cell growth, while Itraconazole disrupts fungal cell membrane formation, resulting in a comprehensive antifungal effect.\n\nUses\n\nCONARIS T200 is primarily prescribed for the management of:\n\nDermatophytosis (Ringworm, Tinea Infections)\nTreats fungal infections affecting skin, nails, and scalp.\n\nOnychomycosis (Fungal Nail Infection)\nHelps in eliminating nail fungus and promotes healthy nail growth.\n\nCandidiasis (Yeast Infections)\nEffective against mucocutaneous and superficial candidal infections.\n\nOther Superficial Fungal Infections\nUseful in treating skin infections caused by dermatophytes, yeasts, and other fungi.\n\nThis combination is particularly beneficial for chronic, resistant, or recurrent fungal infections.\n\nBenefits\n1. Broad-Spectrum Antifungal Activity\n\nThe dual action of Terbinafine and Itraconazole ensures effectiveness against a wide range of fungi, providing comprehensive treatment.\n\n2. Faster Symptom Relief\n\nPatients experience reduced itching, redness, scaling, and discomfort sooner than with single antifungal therapy.\n\n3. Promotes Healing\n\nSupports the restoration of healthy skin and nails, improving appearance and comfort.\n\n4. Reduces Recurrence\n\nThe combination therapy helps prevent fungal infections from returning, especially in chronic or resistant cases.\n\n5. Convenient Oral Administration\n\nOnce- or twice-daily tablet dosing improves patient compliance compared to topical treatments.\n\n6. Suitable for Adults\n\nFormulated for adult patients suffering from persistent fungal infections that require systemic therapy.\n\nDosage\n\nThe recommended dose of CONARIS T200 is usually one tablet once daily, or as directed by a physician.\n\nDuration of therapy depends on the type and severity of infection:\n\nSkin infections: Typically 2–4 weeks\n\nNail infections: May require 6–12 weeks or longer for full recovery\n\nImportant Instructions:\n\nSwallow the tablet whole with water.\n\nTake the medicine after food to reduce stomach upset.\n\nDo not skip doses and complete the full course even if symptoms improve.\n\nAlways follow the prescribing doctor’s instructions to ensure optimal results.\n\nSide Effects\n\nCONARIS T200 is generally well-tolerated, but some patients may experience mild side effects:\n\nNausea and vomiting\n\nStomach discomfort or indigestion\n\nHeadache\n\nDizziness\n\nSerious but Rare Side Effects\n\nLiver function disturbances\n\nAllergic reactions such as rash or swelling\n\nSevere gastrointestinal discomfort\n\nIf any unusual or severe symptoms appear, consult a healthcare professional immediately.\n\nPrecautions and Warning\n\nLiver and Kidney Disorders: Use with caution; liver function tests may be recommended during therapy.\n\nPregnancy and Breastfeeding: Consult your doctor before use; safety has not been fully established.\n\nDrug Interactions: Inform your doctor about other medications, particularly antacids, anticoagulants, or statins.\n\nAllergy: Avoid if allergic to Terbinafine, Itraconazole, or any other ingredient in the tablet.\n\nAlcohol Consumption: Limit alcohol intake, as it may increase the risk of liver-related side effects.\n\nConclusion\n\nCONARIS T200 (Terbinafine 250 mg + Itraconazole 200 mg) is an effective and trusted antifungal combination for the treatment of a variety of superficial and chronic fungal infections. By targeting fungi through dual mechanisms, it provides faster relief, promotes healing, and helps prevent recurrence. With proper dosing, adherence to medical advice, and monitoring for side effects, CONARIS T200 offers a comprehensive solution for adults dealing with persistent fungal infections, helping restore healthy skin, nails, and overall comfort.", "price": 204.0, "discountamount": 61.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2247, "imageuri": "https://productimages.withfloats.com/actual/69400389f34633ae3de3f8f4.png", "tileimageuri": "https://productimages.withfloats.com/tile/69400389f34633ae3de3f8f4.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-15T12:48:07.707Z", "updatedon": "2025-12-16T05:48:08.096Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/terbinafine-and-itraconazole-tablets-250-200mg/2247", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "CONARIS T200", "category": "DERMATALOGY", "tags": [ "terbinafine and itraconazole tablets", "terbinafine and itraconazole", "terbinafine and itraconazole combination", "terbinafine and itraconazole together", "Fungal infections of the skin", "helping restore healthy skin" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }